S

    SGMO (SGMO)

    Official site

    BIOTECHNOLOGY

    $0.07
    +0.00 (+0.00%)

    Last updated: Aug 28, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    51%(20/39)
    Avg Surprise
    -4.26%

    Upcoming Estimates

    Jun 30, 2026
    EPS Consensus$-0.05
    Range$-0.05 - $-0.05
    1 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.04+20.0%
    60d ago$-0.04+20.0%
    30d ago$-0.07-30.0%
    7d ago$-0.07-30.0%
    Current$-0.05
    Revenue Consensus
    $10M
    Range$0 - $27M
    4 analysts
    Sep 30, 2026
    EPS Consensus$-0.05
    Range$-0.05 - $-0.05
    1 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.04+30.0%
    60d ago$-0.04+30.0%
    30d ago$-0.07-40.0%
    7d ago$-0.07-40.0%
    Current$-0.05
    Revenue Consensus
    $9M
    Range$0 - $29M
    4 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.03---
    Sep 26EST
    		-$-0.05---
    Jun 26EST
    		-$-0.05---
    Mar 26
    		$-0.08$0.04-300.00%Miss+42.9%
    Dec 25
    		$-0.07$-0.01-446.97%Miss+34.4%
    Sep 25
    		$-0.11$-0.10-10.00%Miss-375.0%
    Jun 25
    		$-0.08$-0.12+33.33%Beat+52.9%
    Mar 25
    		$-0.14$-0.13-7.69%Miss+44.0%
    Dec 24
    		$-0.11$-0.09-21.01%Miss+67.6%
    Sep 24
    		$0.04$-0.04+200.00%Beat+112.1%
    Jun 24
    		$-0.17$-0.16-6.25%Miss+55.3%
    Mar 24
    		$-0.25$-0.24-4.17%Miss-308.3%
    Dec 23
    		$-0.34$-0.26-30.77%Miss-6.3%
    Sep 23
    		$-0.33$-0.29-13.79%Miss+2.9%
    Jun 23
    		$-0.38$-0.32-18.75%Miss-31.0%
    Mar 23
    		$0.12N/A+136.36%Beat+140.0%
    Dec 22
    		$-0.32$-0.36+11.11%Beat-23.1%
    Sep 22
    		$-0.34$-0.36+5.56%Beat-3.0%
    Jun 22
    		$-0.29$-0.34+14.71%Beat+12.1%
    Mar 22
    		$-0.30$-0.29-3.45%Miss+6.3%
    Dec 21
    		$-0.26$-0.35+25.71%Beat+10.3%
    Sep 21
    		$-0.33$-0.33+0.00%Beat-3200.0%
    Jun 21
    		$-0.33$-0.31-6.45%Miss-26.9%
    Mar 21
    		$-0.32$-0.29-10.34%Miss+13.5%
    Dec 20
    		$-0.29$-0.21-38.10%Miss-514.3%
    Sep 20
    		$-0.01N/A+96.00%Beat+95.8%
    Jun 20
    		$-0.26$-0.34+23.53%Beat+0.0%
    Mar 20
    		$-0.37$-0.35-5.71%Miss+9.8%
    Dec 19
    		$0.07N/A+121.21%Beat+138.9%
    Sep 19
    		$-0.24$-0.34+29.41%Beat-84.6%
    Jun 19
    		$-0.26$-0.35+25.71%Beat-52.9%
    Mar 19
    		$-0.41$-0.24-70.83%Miss-78.3%
    Dec 18
    		$-0.18$-0.21+14.29%Beat-20.0%
    Sep 18
    		$-0.13$-0.18+27.78%Beat+13.3%
    Jun 18
    		$-0.17$-0.15-13.33%Miss+0.0%
    Mar 18
    		$-0.23$-0.18-27.78%Miss+0.0%
    Dec 17
    		$-0.15$-0.18+16.67%Beat-7.1%
    Sep 17
    		$-0.15$-0.19+21.05%Beat+44.4%
    Jun 17
    		$-0.17$-0.22+22.73%Beat-
    Mar 17
    		$-0.23$-0.25+8.00%Beat-
    Dec 16
    		$-0.14$-0.25+44.00%Beat-
    Sep 16
    		$-0.27$-0.25-8.00%Miss-

    Key Metrics

    Valuation
    P/E Ratio-0.22EV/EBITDAN/A
    Price/FCF-0.32xFCF Yield-313.74%
    Profitability
    Profit MarginN/AOperating MarginN/A
    ROEN/AROIC-29534.16%
    Financial Health
    Debt/Equity-1.02xInterest CoverageN/A
    Current Ratio0.70xQuick Ratio0.70x
    Trading Statistics
    BetaN/AAvg VolumeN/A
    52-Week HighN/A52-Week LowN/A

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.07
    SMA 20$0.07
    SMA 50$0.08
    SMA 200$0.27
    EMA 10$0.07
    EMA 20$0.07
    EMA 50$0.09
    EMA 200$0.26

    MACD

    Line: -0.00Signal: -0.00Hist: 0.00

    ADX

    ADX: 32.5+DI: 17.1-DI: 34.0

    Aroon & PSAR

    Aroon Up100.0
    Aroon Down100.0
    PSAR$0.06

    Bollinger Bands

    Upper Band$0.07
    Lower Band$0.07
    %B PositionN/A
    Band Width0.06

    RSI (14-Day)

    Oversold
    27.9

    Momentum Oscillators

    Stoch %KN/A
    Stoch %DN/A
    Williams %RN/A
    ROC (10d)N/A
    MomentumN/A
    CCI (20d)N/A
    MFI (14d)N/A

    Volatility Measures

    ATR (14d)$0.00(1.5%)
    StdDev (20d)N/A
    Hist VolN/A

    Volume Flow

    VWAP$0.07
    OBV-17.1M
    AD Line-289.6M
    CMF (20d)N/A

    Volume Metrics

    Avg Vol (20d)N/A
    Vol RatioN/A
    VWMA (20d)N/A

    Pivot Points

    R3$0.07
    R2$0.07
    R1$0.07
    Pivot Point$0.07
    S1$0.07
    S2$0.07
    S3$0.07

    Advanced Oscillators

    TSI-46.00
    Ultimate OscN/A
    KSTN/A

    Financial Data

    QuarterMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Total Revenue$1.44M$14.23M$581,000$18.31M$6.44M$7.55M$49.41M$356,000$481,000$2.04M$9.40M$6.83M
    Cost of RevenueN/A$1.88M$1.90MN/AN/A$2.13M$2.13M$2.57M$2.53M$2.98M$57.09M$59.25M
    Gross Profit$1.44M$14.23M$581,000$18.31M$6.44M$7.55M$49.41M$356,000$481,000$2.04M$-47,691,000$-52,411,000
    Operating Expenses$33.39M$39.20M$36.13M$36.16M$36.06M$33.54M$38.78M$37.44M$52.01M$64.10M$58.72M$71.16M
    R&D$26.57M$31.44M$28.14M$27.08M$26.01M$23.68M$27.73M$24.22M$35.89M$50.71M$57.09M$63.05M
    SG&A$6.82M$7.76M$7.99M$9.08M$10.06M$9.87M$11.05M$12.04M$11.77M$13.10M$13.92M$14.81M
    Operating Income$-31,946,000$-24,968,000$-35,553,000$-17,855,000$-29,628,000$-25,990,000$10.63M$-37,084,000$-51,526,000$-62,059,000$-106,408,000$-123,572,000
    Interest Income$300,000$252,000$355,000$386,000$309,000$2.17M$129,000$416,000$451,000$1.49M$3.52M$0
    Interest Expense$0$13.00M$0$2.10M$850,000$0$0$0$0$113.85M$0$0
    Income Before Tax$-30,995,000$-37,972,000$-35,091,000$-19,959,000$-30,478,000$-23,823,000$10.76M$-36,054,000$-48,991,000$-60,567,000$-102,893,000$-120,770,000
    Income Tax Expense$0$-553,000$-161,000$27,000$119,000$-427,000$88,000$74,000$98,000$-272,000$1.27M$-6,264,000
    Net Income$-30,995,000$-37,419,000$-34,930,000$-19,986,000$-30,597,000$-23,396,000$10.67M$-36,128,000$-49,089,000$-60,295,000$-104,163,000$-114,506,000
    EBITDA$-31,069,000$-23,085,000$-33,193,000$-18,062,000$-27,704,000$-23,855,000$12.76M$-33,339,000$-44,651,000$-58,754,000$-56,116,000$-62,969,000
    EBIT$-31,946,000$-24,968,000$-35,091,000$-19,959,000$-29,628,000$-25,990,000$10.63M$-35,912,000$-47,177,000$-61,763,000$-61,609,000$-67,225,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about SGMO

    News

    Sangamo Therapeutics Inc Market Sentiment

    This article provides an overview of market sentiment for Sangamo Therapeutics Inc (SGMO), detailing analyst consensus, short interest, options flow, and insider activity. It highlights a "Buy" consensus from analysts with an average price target significantly above the current stock price, alongside recent analyst actions including both maintenance of "Buy" ratings and some downgrades to "Equal-Weight" or "Overweight." The piece also touches on recent news regarding 52-week lows for various stocks and a notable insider stock sale.

    Benzinga España•7/29/26•
    Somewhat-Bearish

    Sangamo Therapeutics, Inc. Revenue Breakdown – DUS:GBY

    This article provides a revenue breakdown for Sangamo Therapeutics, Inc. (GBY) on the Dusseldorf Stock Exchange. It highlights that in the last year, the company generated 33.68 million EUR, primarily from its "Zinc Finger Epigenetic Regulators" segment, which also represented the entire revenue from the United States. This figure is a decrease from 55.83 million EUR in the previous year.

    TradingView•7/29/26•
    Neutral

    Sangamo Therapeutics, Inc. Revenue Breakdown – OTC:SGMOQ

    Sangamo Therapeutics, Inc. (OTC:SGMOQ) generated $39.55 million in revenue last year, primarily from its Zinc Finger Epigenetic Regulators segment. This represents a decrease from the previous year's revenue of $57.80 million. The United States was the primary contributor to the company's revenue.

    TradingView•7/26/26•
    Neutral

    Sangamo looks to switch lenders mid-bankruptcy as it eyes a quick sale process

    Sangamo Therapeutics is seeking to switch lenders during its bankruptcy process to save at least $400,000. This move comes as the company anticipates another month before its assets are liquidated in a quick sale. The article highlights Sangamo's financial struggles and the ongoing process of managing its bankruptcy.

    The Business Journals•7/22/26•
    Bearish

    Sangamo Therapeutics Received Notice of Delisting

    Sangamo Therapeutics (SGMOQ) has received a notice of delisting from Nasdaq. The company's request to continue its listing was denied by Nasdaq's Hearings Panel on July 14, 2026, and it does not plan to seek further review. Trading of Sangamo Therapeutics common stock has already moved to the OTC markets under the symbol SGMOQ.

    TradingView•7/20/26•
    Neutral

    Frequently Asked Questions About SGMO

    Does SGMO pay dividends?
    SGMO (SGMO) does not currently pay a regular dividend.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In